It is easy to take the body’s everyday miracles, like blood clotting, for granted. It turns out that just a simple little cut causes a hugely complex series of reactions – a cascade of events that quickly seal up a cut in a blood vessel. (Can you imagine the alternative? Literally – death from paper cuts.)
However, some people are unique in their ability to form clots more easily. This function may have been a superpower in ages past — like not bleeding to death from a sword wound. But superpowers have their downsides, and a greater risk of dying from a heart attack, stroke, or pulmonary embolism definitely qualifies as a ‘downside’.
This article covers six different genes and the seven genetic variants that increase the risk of blood clots. It is a timely topic — blood clots seem to be a serious complication for people with COVID-19.
Overview of how blood clots form:
When you get a cut or tear in a blood vessel, the first action is that the platelets flowing through the bloodstream jump into the gap. They seal up the broken blood vessel preventing too much blood loss. The platelets must link up and connect with the edges of the cut and then with each other.
Next up is the coagulation cascade. This action is where various coagulation factors become activated. The coagulation factors are proteins that are also called clotting factors. They are inactive when flowing through the bloodstream (so they don’t clog everything up). When the coagulation factors activate, they can quickly form a blood clot.
The final step in clotting is fibrin’s ability to shore up the clot. Next, the body starts breaking down the clot through a process called fibrinolysis. It becomes a balance of adding fibrin and breaking it down.
Going a little deeper: More about platelets
Platelets form from megakaryocyte cells in the bone marrow and lungs. Tiny in size, platelets only survive for 7 to 10 days. These little clot formers have no nucleus (thus, no nuclear DNA). They contain mitochondria, along with granules containing different chemical signals and factors needed for coagulation.
When platelets are zipping around throughout the body, they are not ‘sticky’. Instead, they are in an inactivated form that allows them to flow freely through your veins.
On the cell membrane of platelets are receptors that link to collagen. When a blood vessel tears, platelets bind to the collagen exposed at the rupture site. This binding causes the platelets to change shape and secrete chemical signals, initiating the coagulation cascade.[ref]
In addition to platelets binding to exposed collagen, another molecule called the von Willebrand factor (VWF) can also bind to both collagen and the platelet. In a sense, the von Willebrand factor forms a bridge between platelets and the surface of the blood vessel, and your circulating level of von Willebrand factor is important in how long it takes you to clot.[ref]
When platelets bind to either collagen or the von Willebrand factor, the activation of a signaling cascade occurs, releasing granules from the platelets. The release includes fibrinogen, ADP, serotonin, as well as other molecules, and the activation of COX-1 (which is inhibited by aspirin).[ref]
The figure below depicts all platelet functions – from coagulation and wound healing to immune functions. Creative Commons Image[ref]
So how many of these little guys are zipping around the body? A healthy adult has between 150,000 and 450,000 platelets per microliter of blood.
- A low platelet count (less than 150,000/ul) is known as thrombocytopenia
- A high platelet count (greater than 450,000/ul) is called thrombocytosis
Let’s dig a little deeper into the coagulation cascade so that the genetic variants (listed below) involved in increased clotting make a little more sense. Basically – this is a whole cascade of events that happens quickly and results in the formation of cross-linked fibrin, which forms a mesh to keep the clot together.
The coagulation factors are numbered and referred to with Roman numerals -for example, factor five is written as factor V. Coagulation factors are found both in the plasma (e.g., factor IV) and the endothelial cells that form blood vessels (factors III and VIII).
The coagulation cascade can be divided into two pathways: the extrinsic and intrinsic pathways[ref]
- In the extrinsic pathway, tissue factor activates factor VII. The activated factor VII then activates factor X and factor IX. Factor X binds to activated factor V (along with a calcium molecule) and this causes the activation of prothrombin into thrombin. Thrombin converts fibrinogen into fibrin.
- The intrinsic pathway is also called the contact pathway. After thrombin formation, factor XI activates, causing further activation of factor X and factor IX. Factor X then binds with activated factor V, creating more thrombin. (This is a minor player in the clotting game.)
Finally, all of this results in a fibrin polymer mesh created through the involvement of activated factor XIII. This mesh then holds the clot together, binding the platelets with the other factors.
After the clot forms, it balances out with the activation of plasminogen, an enzyme that breaks down some of the fibrin in the clot. Basically, there is a balancing act of forming the clot and breaking down the clot while the wound heals.
D-dimer releases as clots break down and are often measured in the blood to determine if someone has a blood clot.
Thrombosis: blood clots forming inside a blood vessel
While it is easy to visualize the blood clotting process when you think of a paper cut on your finger, this same process can take place in blood vessels deep inside you. Instead of a cut, there are a variety of different ‘insults’ to the blood vessel that can cause a clot to form.
So what is the big deal about ‘thrombosis’? Why do we care about blood clotting in a blood vessel?
The majority of heart attacks and about 80% of strokes are caused by blood clots.
Blood clots forming deep in the leg are called deep vein thrombosis (DVT). The clot can block blood from flowing past it, or it could break free and travel through the veins, lodging in the lungs, causing a pulmonary embolism. Anticoagulant medications treat blood clots but come with risks of excess bleeding. In all, the case-fatality rates for DVT and pulmonary embolisms are between 5 and 10% over the course of 30 days.[ref]
Thrombosis due to viral or bacterial infections:
Blood clots can also form due to an infection caused by bacteria or viruses.
Blood clots, though, aren’t unique to COVID-19. Instead, they are a risk factor in many severe infectious diseases, including influenza and staph infections. In fact, people with severe complications from the H1N1 strain of the flu were at an 18 to 23-fold greater risk for blood clots.[ref][ref]
When the body actively fights off an infection, a lot of proinflammatory cytokines (IL-6, TNF-alpha, IL-1, IFNγ) are released. These cytokines cause leukocytes (white blood cells) and the surrounding epithelial cells to release procoagulants, such as tissue factors. These procoagulants can tip the body towards too much coagulation, with platelets clumping together. It can cause small clots to form, plugging up small blood vessels. The kidneys, liver, lungs, and brain are particularly vulnerable.[ref][ref]
Infection by bacteria or viruses increases the risk of thrombosis by 2 to 20-fold. The risk is greatest when the infection is active – and in the first few weeks after the infection. Complications from clots, such as strokes, are common in the first three days after respiratory infections and urinary tract infections.[ref]
ARDS (acute respiratory distress syndrome) is a severe complication of pneumonia due to viral or bacterial infections. Research shows that bacterial pneumonia causes “increased platelet aggregation, pulmonary microvascular thrombosis, endothelial damage, and hyper-inflammatory cytokine responses.”[ref]
DIC – disseminated intravascular coagulation:
In severe infections, such as sepsis, a condition called disseminated intravascular coagulation (DIC) can occur. DIC causes increased coagulation in the small blood vessels and micro-clots to form in various organs.[ref]
The increased number of clots then causes a depletion of platelets and clotting factors. So, on the one hand, you have a lot of little blood clots, but on the other hand, you eventually increase bleeding risk due to the decreased platelets and decreased fibrinogen. These clots also lead to elevated levels of D-dimer, which releases when the fibrin clots break down.
Genetic variants that increase the risk of blood clots:
Not a member? Join here. Membership lets you see your data right in each article and also gives you access to the member’s only information in the Lifehacks sections.
F2 gene: Prothrombin variants
The F2 gene codes for factor 2, also known as prothrombin. When activated, prothrombin becomes thrombin, which is important in fibrin creation. The variant listed below is known as G20210A, and is linked to an increased risk of blood clots and strokes.
About 2% of Caucasians carry the G20210A variant, but it is much less common in Asians, Africans, and Native Americans. A meta-analysis of the data from a bunch of studies found that carrying the G20210A variant increased the risk of thromboembolism by 2.6 to 4.4-fold (depending on the location of the clot). The risk of DVT is also significantly increased in carriers of both G20210A and the factor V Leiden (F5 gene, below) variants.[ref]
Check your genetic data for rs1799963, G20210A (23andMe v4, v5 – i3002432; AncestryDNA):
- A/A: a large increase in the risk of blood clots, increased risk of stroke with PFO
- A/G: increased risk of blood clots, increased risk of stroke with PFO
- G/G: typical
Members: Your genotype for rs1799963 (i3002432) is .
F5 Gene: Factor V Leiden variant
Factor V, coded for by the F5 gene, is a coagulation protein mainly synthesized in the liver and then circulated through the body. It is activated in clotting by thrombin and can bind to activated platelets. Just as there is a cascade of events that cause a blood clot to form quickly, other molecules, such as protein C, turn off the clotting when it is no longer needed.[ref]
The F5 gene variant, known as factor V Leiden, has links in many studies to an increased risk of deep vein thrombosis and pulmonary embolism. A meta-analysis that combined data from 31 studies estimates that the increase in the risk of thrombosis for people carrying one copy of the variant was 4-fold, and the increase for those carrying two copies was 11-fold.[ref][ref][ref][ref]
Check your genetic data for rs6025 (23andMe v4, v5; AncestryDNA):
- C/C: typical
- C/T: one copy of factor V Leiden
- T/T: two copies of factor V Leiden
Members: Your genotype for rs6025 is —.
ITGB3 Gene: PIA1/A2 mutation
The ITGB3 gene codes for the fibrinogen receptor, part of how platelets form clots.
One well-studied ITGB3 genetic variant is known as PIA1/A2. Studies show that people who carry the A2 variant have faster clotting times. It also has links to an increased risk of heart attacks and deep vein thrombosis (blood clots).[ref][ref][ref][ref]
Check your genetic data for rs5918 (23andMe v4, v5; AncestryDNA):
- C/C: two copies of the A2 variant, increased risk of heart disease, may not benefit from aspirin for heart attack prevention, protection against Hantavirus[ref][ref][ref]
- C/T: somewhat increased risk of heart disease, may not benefit as much from aspirin for heart attack prevention, protection against Hantavirus[ref][ref][ref]
- T/T: typical
Members: Your genotype for rs5918 is —.
VWF gene: von Willebrand factor clotting variants
The VWF gene codes for the von Willebrand factor (VWF) needed for platelets to stick to each other. When circulating through the blood, most of the von Willebrand factor is bound to factor VIII (8). When activated by coagulation factors, factor VIII releases from VWF and becomes part of the activation of factor X and conversion of prothrombin to thrombin (active form).
Higher levels of VWF and factor VIII are risk factors for blood clotting more easily.[ref] People who have decreased von Willebrand factor, though, tend to bleed more easily and may have easy bruising, nosebleeds, and bleeding gums.
People with type O blood typically have lower levels of von Willebrand factor.[ref] (Read about how people with type O blood are at a lower risk of severe COVID-19 complications)
Below, several variants have links to higher VWF levels. Also, mutations exist (not listed here) that lead to easier bleeding and Von Willebrand disease.
Check your genetic data for rs1063856 (23andMe v4, v5):
- T/T: typical
- C/T: likely to have slightly higher Von Willebrand factor,
- C/C: likely to have increased Von Willebrand factor, slightly increased risk of blood clots.[ref][ref]
Members: Your genotype for rs1063856 is —.
Check your genetic data for rs1063857 (23andMe v4; AncestryDNA):
- A/A: typical
- A/G: likely to have slightly higher von Willebrand factor
- G/G: likely to have increased von Willebrand factor[ref]
Members: Your genotype for rs1063857 is —.
G6P gene: platelet stickiness
The G6P gene codes for a protein called glycoprotein VI, which plays an essential role in the aggregation of platelets. Platelets that stick together too easily can be a problem in coronary artery disease.
Check your genetic data for rs1613662 (23andMe v4, v5; AncestryDNA):
- A/A: typical
- A/G: slightly increased platelet stickiness
- G/G: slightly increased platelet stickiness, increased risk of sticky platelet syndrome, slightly increased risk of heart attack[ref][ref]
Members: Your genotype for rs1613662 is —.
F11 gene: Factor XI and thrombosis
The F11 gene codes for the factor XI protein, one of the coagulation factors needed in the coagulation cascade for creating the fibrin net.
Check your genetic data for rs2036914 (23andMe v5; AncestryDNA):
- C/C: increased risk of venous thrombosis, thromboembolism[ref][ref][ref]
- C/T: typical risk
- T/T: typical
Members: Your genotype for rs2036914 is —.
Take the information about your blood clot genetic risk factors as a ‘heads up’.
- Don’t ignore the signs of a blood clot.
- Symptoms of a blood clot in your arm or leg can include swelling, pain, redness, and warmth.
- If you suspect a clot, head to the doctor for an assessment.
- While the risk of blood clots increases with age, people genetically prone to clots can get one at any age.
Natural supplements that act as mild blood thinners:
The rest of this article is for Genetic Lifehacks members only. Consider joining today to see the rest of this article.
Related Articles and Genes:
Acute Respiratory Distress Syndrome (ARDS) genes
ARDS is caused by an overwhelming immune response to a virus, bacteria, or lung injury. Learn more about which of your immune system genes are involved in ARDS.
Viral Immunity: Your genes protect you
Your genetic variants shape your immune system and give you superpowers against some pathogens – and perhaps more susceptible to others.
Non-secretors: Norovirus resistance and gut microbiome
A genetic variant in the FUT2 gene controls whether or not you secrete your blood type into your saliva and other bodily fluids, such as your intestinal mucosa. This alters the gut microbiome – and protects you from Norovirus.
How to log in to 23andMe and download raw data
Step-by-step instructions on how to download your raw data from 23andMe
Arsov, Todor, et al. “Factor V Leiden Is Associated with Higher Risk of Deep Venous Thrombosis of Large Blood Vessels.” Croatian Medical Journal, vol. 47, no. 3, June 2006, pp. 433–39. PubMed Central, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2080416/.
Campello, Elena, et al. “Diagnosis and Management of Factor V Leiden.” Expert Review of Hematology, vol. 9, no. 12, Dec. 2016, pp. 1139–49. PubMed, https://doi.org/10.1080/17474086.2016.1249364.
El-Galaly, Tarec C., et al. “Single Nucleotide Polymorphisms and the Risk of Venous Thrombosis: Results from a Danish Case-Cohort Study.” British Journal of Haematology, vol. 160, no. 6, Mar. 2013, pp. 838–41. PubMed, https://doi.org/10.1111/bjh.12132.
Floyd, Christopher N., et al. “The PlA1/A2 Polymorphism of Glycoprotein IIIa as a Risk Factor for Myocardial Infarction: A Meta-Analysis.” PLOS ONE, vol. 9, no. 7, July 2014, p. e101518. PLoS Journals, https://doi.org/10.1371/journal.pone.0101518.
Fountain, John H., and Sarah L. Lappin. “Physiology, Platelet.” StatPearls, StatPearls Publishing, 2022. PubMed, http://www.ncbi.nlm.nih.gov/books/NBK470328/.
Griffin, Daniel O., et al. “Pulmonary Embolism and Increased Levels of D-Dimer in Patients with Coronavirus Disease.” Emerging Infectious Diseases, vol. 26, no. 8, Aug. 2020, pp. 1941–43. PubMed, https://doi.org/10.3201/eid2608.201477.
Jarvis, Kirsten Brunsvig, et al. “Candidate Single Nucleotide Polymorphisms and Thromboembolism in Acute Lymphoblastic Leukemia – A NOPHO ALL2008 Study.” Thrombosis Research, vol. 184, Dec. 2019, pp. 92–98. PubMed, https://doi.org/10.1016/j.thromres.2019.11.002.
Jiang, Lilong, et al. “Discovery of Glycyrrhetinic Acid as an Orally Active, Direct Inhibitor of Blood Coagulation Factor Xa.” Thrombosis Research, vol. 133, no. 3, Mar. 2014, pp. 501–06. PubMed, https://doi.org/10.1016/j.thromres.2013.12.025.
Khatami, Mehri, et al. “Common Rs5918 (PlA1/A2) Polymorphism in the ITGB3 Gene and Risk of Coronary Artery Disease.” Archives of Medical Sciences. Atherosclerotic Diseases, vol. 1, no. 1, Apr. 2016, pp. e9–15. PubMed Central, https://doi.org/10.5114/amsad.2016.59587.
Kim, Kyung-Min, et al. “Novel Factor Xa Inhibitor, Maslinic Acid, with Antiplatelet Aggregation Activity.” Journal of Cellular Physiology, vol. 235, no. 12, Dec. 2020, pp. 9445–56. PubMed, https://doi.org/10.1002/jcp.29749.
Komsa-Penkova, Regina, et al. “Rs5918ITGB3 Polymorphism, Smoking, and BMI as Risk Factors for Early Onset and Recurrence of DVT in Young Women.” Clinical and Applied Thrombosis/Hemostasis: Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis, vol. 23, no. 6, Sept. 2017, pp. 585–95. PubMed, https://doi.org/10.1177/1076029615624778.
LaPelusa, Andrew, and Heeransh D. Dave. “Physiology, Hemostasis.” StatPearls, StatPearls Publishing, 2022. PubMed, http://www.ncbi.nlm.nih.gov/books/NBK545263/.
Lodigiani, Corrado, et al. “Venous and Arterial Thromboembolic Complications in COVID-19 Patients Admitted to an Academic Hospital in Milan, Italy.” Thrombosis Research, vol. 191, July 2020, pp. 9–14. PubMed, https://doi.org/10.1016/j.thromres.2020.04.024.
Melchinger, Hannah, et al. “Role of Platelet Mitochondria: Life in a Nucleus-Free Zone.” Frontiers in Cardiovascular Medicine, vol. 6, Oct. 2019, p. 153. PubMed Central, https://doi.org/10.3389/fcvm.2019.00153.
—. “Role of Platelet Mitochondria: Life in a Nucleus-Free Zone.” Frontiers in Cardiovascular Medicine, vol. 6, Oct. 2019, p. 153. PubMed Central, https://doi.org/10.3389/fcvm.2019.00153.
Mikkelsson, Jussi, et al. “Glycoprotein IIIa PlA1/A2 Polymorphism and Sudden Cardiac Death.” Journal of the American College of Cardiology, vol. 36, no. 4, Oct. 2000, pp. 1317–23. jacc.org (Atypon), https://doi.org/10.1016/S0735-1097(00)00871-8.
Motovska, Zuzana, et al. “Platelet Glycoprotein GP VI 13254C Allele Is an Independent Risk Factor of Premature Myocardial Infarction.” Thrombosis Research, vol. 125, no. 2, Feb. 2010, pp. e61-64. PubMed, https://doi.org/10.1016/j.thromres.2009.09.002.
Mufti, Ahmad H., et al. “The Common VWF Single Nucleotide Variants c.2365A>G and c.2385T>C Modify VWF Biosynthesis and Clearance.” Blood Advances, vol. 2, no. 13, July 2018, pp. 1585–94. PubMed Central, https://doi.org/10.1182/bloodadvances.2017011643.
Naess, I. A., et al. “Incidence and Mortality of Venous Thrombosis: A Population-Based Study.” Journal of Thrombosis and Haemostasis: JTH, vol. 5, no. 4, Apr. 2007, pp. 692–99. PubMed, https://doi.org/10.1111/j.1538-7836.2007.02450.x.
Obi, Andrea T., et al. “Empirical Systemic Anticoagulation Is Associated with Decreased Venous Thromboembolism in Critically Ill Influenza A H1N1 Acute Respiratory Distress Syndrome Patients.” Journal of Vascular Surgery. Venous and Lymphatic Disorders, vol. 7, no. 3, May 2019, pp. 317–24. PubMed, https://doi.org/10.1016/j.jvsv.2018.08.010.
Oliver, Kendra H., et al. “Pro32Pro33 Mutations in the Integrin Β3 PSI Domain Result in ΑIIbβ3 Priming and Enhanced Adhesion: Reversal of the Hypercoagulability Phenotype by the Src Inhibitor SKI-606.” Molecular Pharmacology, vol. 85, no. 6, June 2014, pp. 921–31. PubMed, https://doi.org/10.1124/mol.114.091736.
Saeed, Anjum, et al. “To Determine the Frequency of Factor V Leiden in Cases of Deep Vein Thrombosis and Healthy Controls.” Pakistan Journal of Medical Sciences, vol. 31, no. 5, Oct. 2015, pp. 1219–22. PubMed, https://doi.org/10.12669/pjms.315.8088.
Simone, Benedetto, et al. “Risk of Venous Thromboembolism Associated with Single and Combined Effects of Factor V Leiden, Prothrombin 20210A and Methylenetethraydrofolate Reductase C677T: A Meta-Analysis Involving over 11,000 Cases and 21,000 Controls.” European Journal of Epidemiology, vol. 28, no. 8, Aug. 2013, pp. 621–47. PubMed, https://doi.org/10.1007/s10654-013-9825-8.
Skjeflo, E. W., et al. “Staphylococcus Aureus-Induced Complement Activation Promotes Tissue Factor-Mediated Coagulation.” Journal of Thrombosis and Haemostasis, vol. 16, no. 5, 2018, pp. 905–18. Wiley Online Library, https://doi.org/10.1111/jth.13979.
—. “Staphylococcus Aureus-Induced Complement Activation Promotes Tissue Factor-Mediated Coagulation.” Journal of Thrombosis and Haemostasis, vol. 16, no. 5, 2018, pp. 905–18. Wiley Online Library, https://doi.org/10.1111/jth.13979.
Smith, Nicholas L., et al. “Genetic Variation Associated with Plasma von Willebrand Factor Levels and the Risk of Incident Venous Thrombosis.” Blood, vol. 117, no. 22, June 2011, pp. 6007–11. PubMed Central, https://doi.org/10.1182/blood-2010-10-315473.
Suchon, Pierre, et al. “Common Risk Factors Add to Inherited Thrombophilia to Predict Venous Thromboembolism Risk in Families.” TH Open: Companion Journal to Thrombosis and Haemostasis, vol. 3, no. 1, Jan. 2019, pp. e28–35. PubMed Central, https://doi.org/10.1055/s-0039-1677807.
Swystun, Laura L., and David Lillicrap. “Genetic Regulation of Plasma von Willebrand Factor Levels in Health and Disease.” Journal of Thrombosis and Haemostasis : JTH, vol. 16, no. 12, Dec. 2018, pp. 2375–90. PubMed Central, https://doi.org/10.1111/jth.14304.
Szczeklik, Andrzej, et al. “Relationship between Bleeding Time, Aspirin and the PlA1/A2 Polymorphism of Platelet Glycoprotein IIIa.” British Journal of Haematology, vol. 110, no. 4, 2000, pp. 965–67. Wiley Online Library, https://doi.org/10.1046/j.1365-2141.2000.02267.x.
Tabeshpour, Jamshid, et al. “The Regulatory Role of Curcumin on Platelet Functions.” Journal of Cellular Biochemistry, vol. 119, no. 11, Nov. 2018, pp. 8713–22. PubMed, https://doi.org/10.1002/jcb.27192.
Tang, Weihong, et al. “Gene-Centric Approach Identifies New and Known Loci for FVIII Activity and VWF Antigen Levels in European Americans and African Americans.” American Journal of Hematology, vol. 90, no. 6, June 2015, pp. 534–40. PubMed Central, https://doi.org/10.1002/ajh.24005.
Undas, A., et al. “Pl(A2) Polymorphism of Beta(3) Integrins Is Associated with Enhanced Thrombin Generation and Impaired Antithrombotic Action of Aspirin at the Site of Microvascular Injury.” Circulation, vol. 104, no. 22, Nov. 2001, pp. 2666–72. PubMed, https://doi.org/10.1161/hc4701.099787.
Wei, Guangyu, et al. “Salidroside Inhibits Platelet Function and Thrombus Formation through AKT/GSK3β Signaling Pathway.” Aging, vol. 12, no. 9, Apr. 2020, pp. 8151–66. PubMed, https://doi.org/10.18632/aging.103131.
Xing, Changyang, et al. “Lung Ultrasound Findings in Patients with COVID-19 Pneumonia.” Critical Care, vol. 24, Apr. 2020, p. 174. PubMed Central, https://doi.org/10.1186/s13054-020-02876-9.